VINCRISTINE

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Damage to nearby tissue if the medication leaks from a vein

Jaw pain

 

PROMPT:

Within 2-3 weeks, prior to the next course

Hair Loss

Weakness, constipation

Absent intestinal activity resulting in intestinal blockage, drooping eyelid, hoarseness, decrease in the number of red and white blood cells and platelets made in the bone marrow, reduced function of the brain, abnormal hormone function affecting levels of salt in the blood and urine, causing too much or too little urine, seizures

DELAYED:

Any time later during therapy, excluding the above conditions

Loss of deep tendon reflexes

Numbness, tingling and clumsiness

 

 

 

 

 

 

DOXORUBICIN

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Abnormal heart rhythm, nausea, worsening of side effects due to radiation treatments, pink or red color to urine, damage to the skin of medication leaks from a vein

 

Allergic reaction (sometimes life threatening), rash

PROMPT:

Within 2-3 weeks, prior to the next course

decrease in the number of red and white blood cells and platelets made in the bone marrow, decreased ability of the body to fight infection and disease, hair loss

Mouth sores, damage to the liver

Rash

DELAYED:

Any time later during therapy, excluding the above conditions

 

 

Weakness of the heart muscle, the chance of which is higher with higher doses

LATE:

Any time after completion of treatment

A new cancer or leukemia resulting from this treatment

 

 

 

 

 

CYCLOPHOSPHAMIDE

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Loss of appetite, nausea, vomiting

Metallic taste, abnormal hormone function affecting levels of salt in the blood and urine, causing too much or too little urine

Temporary blurred vision, heart damage with abnormal heart rhythms, decay of muscle tissue in the heart

PROMPT:

Within 2-3 weeks, prior to the next course

decrease in the number of red and white blood cells and platelets made in the bone marrow, hair loss

Bleeding and inflammation of the urinary bladder

 

DELAYED:

Any time later during therapy, excluding the above conditions

Decreased ability of the body to fight infection or disease, absence of sperm or stopped monthly periods, inability to have children

 

Damage/scarring of lung tissue

LATE:

Any time after completion of treatment

A new cancer or leukemia resulting from this treatment

 

 

 

 

 

MESNA

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Bad taste when taken by mouth

Nausea, vomiting, stomach pain

Headache, pain in arms, legs and joints, tired feeling, rash, temporary low blood pressure, allergic reaction

PROMPT:

Within 2-3 weeks, prior to the next course

 

 

Diarrhea

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

G-CSF

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

 

Irritation at the site of injection

Allergic reaction, low fever

PROMPT:

Within 2-3 weeks, prior to the next course

 

Ache or pain inside of bones, increased levels of liver enzymes and uric acid in the blood, low number of platelets in the blood

Enlargement of the spleen, worsening of pre-existing skin rashes, hair loss

DELAYED:

Any time later during therapy, excluding the above conditions

 

 

Inflammation of a blood vessel in the skin

 

 

 

 

 

 

 

 

 

 

 

 

ETOPOSIDE

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Nausea, vomiting

 

Low blood pressure, allergic reaction (sometimes life threatening) skin rash

PROMPT:

Within 2-3 weeks, prior to the next course

decrease in the number of red and white blood cells and platelets made in the bone marrow

Hair loss, worsens side effects due to radiation treatments, diarrhea

Numbness, tingling, clumsiness, mouth sores

LATE:

Any time after completion of treatment

A new cancer or leukemia resulting from this treatment

 

 

 

 

 

 

 

 

 

 

 

CISPLATIN

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Nausea, vomiting

Metallic Taste

Allergic reaction

PROMPT:

Within 2-3 weeks, prior to the next course

Loss of appetite, low level of magnesium salts in the blood, hearing loss (high sounds) damage to kidney tissue, decrease in the number of red and white blood cells and platelets made in the bone marrow

Abnormal levels of certain salts in the body like sodium and potassium

Numbness, tingling, clumsiness, ringing in the ears, seizure, damage to the liver

DELAYED:

Any time later during therapy, excluding the above conditions

 

Hearing loss in the normal hearing range

 

LATE:

Any time after completion of treatment

A new cancer or leukemia resulting from this treatment

 

 

 

 

 

 

 

 

 

 

MELPHALAN

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Loss of appetite, nausea, vomiting, sores if drugs leak from vein

 

Low blood pressure, excessive perspiration, allergic reaction

PROMPT:

Within 2-3 weeks, prior to the next course

decrease in the number of red and white blood cells and platelets made in the bone marrow

 

 

DELAYED:

Any time later during therapy, excluding the above conditions

 

Weakness and weight loss

 

LATE:

Any time after completion of treatment

Damage/scarring of lung tissue, a new cancer or leukemia resulting from this treatment

 

 

 

 

 

 

 

CARBOPLATIN

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

Nausea, vomiting

 

Metallic Taste

PROMPT:

Within 2-3 weeks, prior to the next course

Low number of white blood cells and platelets

Abnormal levels of certain salts in the body like sodium and potassium

Numbness, tingling, clumsiness, ringing in the ears, seizure, damage to the liver

LATE:

Any time after completion of treatment

A new cancer or leukemia resulting from this treatment

 

TOPOTECAN

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

 

Nausea, vomiting, diarrhea, mouth sores, flu-like symptoms, headache, rashes, increased liver enzymes in the blood

Stomach pain, shaking chills

PROMPT:

Within 2-3 weeks, prior to the next course

decrease in the number of red and white blood cells and platelets made in the bone marrow

 

 

DELAYED:

Any time later during therapy, excluding the above conditions

 

Loss of strength or energy

Tiny amounts of blood in the urine

 

 

 

 

 

 

 

 

 

13-CIS-RETINOIC ACID

COMMON

Happens to 21-100 children out of 100

OCCASIONAL

Happens to 5-20 children out of 100

RARE

Happens to <5 children out of 100

IMMEDIATE:

Within 1-2 days of receiving drug

 

Nausea, vomiting,

 

PROMPT:

Within 2-3 weeks, prior to the next course

 

 

 

1